Wednesday, July 8, 2026

pharma · IC - Interstitial Cystitis · Interstitial Cystitis · LIPO

LIPELLA PHARMACEUTICALS

LIPELLA PHARMACEUTICALS clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Pittsburgh, USA HQ
2005 Founded
3 Employees
Public company Type
LIPO · NYSE Ticker
Company details
Status
Public
HQ
Pittsburgh, USA
Founded
2005
Employees
3
Programs
4
Drugs
3
Patents
4
Intelligence · Clinical Programs

LIPELLA PHARMACEUTICALS projects

4 ClinicalTrials.gov programs sponsored by LIPELLA PHARMACEUTICALS.

LIPELLA PHARMACEUTICALS has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. LP-08 80mg

    LIPELLA PHARMACEUTICALS INC.

    Interstitial Cystitis

    phase 2 small molecule completed

    1 trial
  2. LP-10

    LIPELLA PHARMACEUTICALS INC.

    Hemorrhagic Cystitis

    phase 2 small molecule completed

    1 trial
  3. LP-10 (Liposomal Tacrolimus)

    LIPELLA PHARMACEUTICALS INC.

    Oral Lichen Planus

    phase 2 small molecule active

    1 trial
  4. Ferumoxytol

    LIPELLA PHARMACEUTICALS INC.

    IC - Interstitial Cystitis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does LIPELLA PHARMACEUTICALS have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.